BioCardia closed at $0.89 on Nov 5, down 2.53%, 39.5% below its 52-week closing high. Volume of 136.8K shares was 1.16× its 20-day average (close to normal).
Split-adjusted performance: -18.3% over one month, -18.3% over six months, -33.1% over one year.
Short interest was 678.4K shares at the Oct 15 settlement, up 9.6% from the prior report (6.2% of float, 5.0 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| BCDABioCardia | $0.8900 | −2.53% | −18.3% | — | — | — | $13.5M | |
| DYAIDyadic International | $0.3401 | −7.25% | −54.3% | −0.6% | −221.0% | — | $13.6M | Compare |
| TCRXTScan Therapeutics | $0.1818 | −13.43% | −85.0% | −65.8% | −2888.6% | — | $12.3M | Compare |
| ATYRaTyr Pharma | $6.03 | −2.43% | −83.6% | — | — | — | $15.1M | Compare |
| SCLXScilex Holding | $1.70 | −7.10% | −78.9% | −22.8% | −1501.3% | — | $12.0M | Compare |
| ABOSAcumen Pharmaceuticals | $0.2138 | −1.16% | −91.3% | — | — | — | $15.5M | Compare |
| JSPRJasper Therapeutics | $0.4692 | −8.20% | −48.3% | — | — | — | $15.6M | Compare |
| PLURPluri | $1.19 | −3.26% | −64.4% | −15.8% | −1755.2% | — | $16.1M | Compare |
| PASGPassage Bio | $3.46 | −1.42% | −15.2% | — | — | — | $11.1M | Compare |
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
